BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 36350138)

  • 1. Using a machine learning algorithm to predict outcome of primary cytoreductive surgery in advanced ovarian cancer.
    Piedimonte S; Erdman L; So D; Bernardini MQ; Ferguson SE; Laframboise S; Bouchard Fortier G; Cybulska P; May T; Hogen L
    J Surg Oncol; 2023 Mar; 127(3):465-472. PubMed ID: 36350138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Integrated Prediction Model algorithm for outcome of cytoreduction in advanced ovarian cancer.
    Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Avery L; May T; Hogen L
    Int J Gynecol Cancer; 2023 Jul; 33(7):1077-1082. PubMed ID: 37015756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated prediction model of patient factors, resectability scores and surgical complexity to predict cytoreductive outcome and guide treatment plan in advanced ovarian cancer.
    Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Cybulska P; Avery L; May T; Hogen L
    Gynecol Oncol; 2022 Sep; 166(3):453-459. PubMed ID: 35820987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
    Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
    Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minilaparotomy, Cyfra21-1, and Other Predicting Factors for Suboptimal Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer: A Pilot Study.
    Nantasupha C; Pojchamarnwiputh S; Charoenkwan K
    Asian Pac J Cancer Prev; 2022 Dec; 23(12):4119-4124. PubMed ID: 36579993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
    Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
    JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
    Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
    Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
    Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.
    Suidan RS; Ramirez PT; Sarasohn DM; Teitcher JB; Iyer RB; Zhou Q; Iasonos A; Denesopolis J; Zivanovic O; Long Roche KC; Sonoda Y; Coleman RL; Abu-Rustum NR; Hricak H; Chi DS
    Gynecol Oncol; 2017 Apr; 145(1):27-31. PubMed ID: 28209497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
    Kim SR; Malcolmson J; Li X; Bernardini MQ; Hogen L; May T
    Gynecol Oncol; 2021 Sep; 162(3):702-706. PubMed ID: 34256977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
    Kumar A; Sheedy S; Kim B; Suidan R; Sarasohn DM; Nikolovski I; Lakhman Y; McGree ME; Weaver AL; Chi D; Cliby WA
    Gynecol Oncol; 2019 Jul; 154(1):72-76. PubMed ID: 31000471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.
    Bristow RE; Duska LR; Lambrou NC; Fishman EK; O'Neill MJ; Trimble EL; Montz FJ
    Cancer; 2000 Oct; 89(7):1532-40. PubMed ID: 11013368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of a risk-based algorithm to reduce poor operative outcomes after complex surgery for ovarian cancer.
    Narasimhulu DM; Fagotti A; Scambia G; Weaver AL; McGree M; Quagliozzi L; Langstraat C; Kumar A; Cliby W
    Int J Gynecol Cancer; 2023 Jan; 33(1):83-88. PubMed ID: 36517075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
    Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
    Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diaphragmatic Surgery in Advanced Ovarian, Tubal and Peritoneal Cancer. A 7-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Muallem MZ; Almuheimid J; Richter R; Braicu EI; Osman S; Sehouli J
    Anticancer Res; 2016 Sep; 36(9):4707-13. PubMed ID: 27630317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.